Biofrontera AG:Ad hoc: European Commission authorizes EU-wide marketing and distribution of Biofrontera's Ameluz®
(Thomson Reuters ONE) -
Biofrontera AG /
/
Ad hoc: European Commission authorizes EU-wide marketing and distribution of
Biofrontera's Ameluz®
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Leverkusen, 16 December 2011 -
Biofrontera was today informed by the European Commission that its product
Ameluz(®) ("for the lovers of light", in development called BF-200 ALA) was
approved for distribution throughout the entire EU, Norway, Island and
Liechtenstein. Already in October had the responsible "European Medicines
Agency" recommended the approval that was now ratified. Ameluz(®) is a
prescription-only medicinal product for the treatment of actinic keratosis by
the so-called photodynamic therapy. In such therapies a medicinal product, in
this case Ameluz(®), is combined with a light-treatment. Large pivotal clinical
trials had demonstrated the strong superiority of Ameluz(®) in comparison to its
competitors. With the EU-wide approval, Ameluz(®) can in principle be
distributed immediately, but the manufacturing and the release of Ameluz(®) will
still require some weeks. The first market launch, planned for Germany, is thus
foreseen for the 1(st) of February.
Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611
Contact:
Werner Pehlemann
Biofrontera AG
Tel.: +49 (0214) 87 63 20, Fax.: +49 (0214) 87 63 290
E-mail: w.pehlemann(at)biofrontera.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via Thomson Reuters ONE
[HUG#1572122]
Unternehmensinformation / Kurzprofil:
Datum: 16.12.2011 - 16:11 Uhr
Sprache: Deutsch
News-ID 98000
Anzahl Zeichen: 2214
contact information:
Town:
Leverkusen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 170 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera AG:Ad hoc: European Commission authorizes EU-wide marketing and distribution of Biofrontera's Ameluz®"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
